FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567784973> ?p ?o ?g. }

• W1567784973 abstract "Contributors Preface Chapter 1 A Brief History of Cancer Chemotherapy Summary 1. Introduction 2. Genotoxic (Cytotoxic) Therapy 3. Growth Control Pathways 4. Host-Tumor Interactions 5. Conclusions References Chapter 2 Novel Targets in the Cell Cycle and Cell Cycle Checkpoints Summary 1. Introduction 2. Molecular Regulation of Cell Cycle Progression 3. Molecular Regulation of Cell Cycle Checkpoints 4. Rationale for Targeting Cyclin-Dependent Kinases and Cell Cycle Checkpoint Pathways 5. Agents and Strategies for Therapeutic Interference 6. Conclusions References Chapter 3 Growth Factor and Signal Transduction Targets for Cancer Therapy Summary 1. Introduction 2. The ErbB Family of Receptor Tyrosine Kinases (RTKs) 3. The Ras-Raf-MEK-ERK Signaling Pathway 4. c-Src Kinase, Signal Transduction, Transformation, and Cancer 5. Akt 6. Nuclear Hormone Receptors as Targets for Cancer Therapy 7. Implications for Drug Discovery and Development References Chapter 4 Cell Death Pathways as Targets for Anticancer Drugs Summary 1. Introduction 2. Two Main Pathways for Drug-Induced Apoptosis 3. Modulation of Drug-Induced Cell Death by Bcl-2 and Related Proteins 4. The Central Role of Caspases in Drug-Induced Apoptosis 5. Synergy between Death Receptors and Cytotoxic Drugs 6. The Rel/NF-kB/IkB Proteins 7. Conclusion References Chapter 5 Drug Resistance Pathways as Targets Summary 1. Introduction 2. Targeting Drug Transport 3. Targeting Cellular Stress Responses 4. Targeting DNA Repair Systems 5. Conclusions References Chapter 6 Role of Matrix Metalloproteinases and Plasminogen Activators in Cancer Invasion and Metastasis: Therapeutic Strategies Summary 1. Introduction 2. The Extracellular Matrix 3. Cancer Invasion and Metastasis 4. Cell Adhesion in Cancer 5. Cancer Cell Motility 6. Inflammatory Response to Cancer 7. Proteolytic Enzymes Implicated in Cancer Invasion 8. MMPIs as Novel Anticancer Agents 9. Sheddases 10. The uPA System: Proteolytic Control of MMP Activation References Chapter 7 Tumor Vasculature as a Target Summary 1. Introduction 2. How to Inhibit Tumor Angiogenesis 3. Concluding Remarks References Chapter 8 Gene-Directed Enzyme Prodrug Therapy Summary 1. Introduction 2. Background 3. Enzyme-Prodrug Systems 4. Tailored Prodrugs for GDEPT 5. The Activation Process 6. Augmenting the Effect 7. Exploiting the Bystander Effect and Acquired Immunity 8. Conclusions References Chapter 9 Tumor Antigens as Targets for Anticancer Drug Development Summary 1. Introduction 2. Antigen Targets for Cancer Vaccines 3. Tumor Antigens as Targets for Antibody-Based Therapeutics References Chapter 10 Structure-Based Drug Design and its Contributions to Cancer Chemotherapy Summary 1. Introduction 2. Antimetabolites 3. Protease Inhibitors 4. Protein Kinase Inhibitors 5. Other Targets 6. Novel Methods in Structure-Based Drug Design 7. Conclusions and Current Questions References Chapter 11 The Contribution of Synthetic Organic Chemistry to Anticancer Drug Development Summary 1. Introduction 2. Early Rationality 3. The Random Screening Era: Directly from Screen to Clinic 4. Organic Synthesis Catches Up: Development of National Product Leads 5. Development of Synthetic Compounds: Structure-Activity Relationships 6. Immunotoxins: Synthetic Organic Chemistry Applied to Large Molecules 7. Organic Synthesis in Rational Design: Tumor-Activated Prodrugs of Cytokines 8. Early Genomics: Inhibitors of Transmembrane Tyrosine Kinases 9. The Genomics/Proteomics Era: Combinatorial Chemistry 10. Conclusion References Chapter 12 Biosynthetic Products for Anticancer Drug Design and Treatment: The Bryostatins Summary 1. Introduction 2. Background to the Bryostatins 3. Comprehensive Review of Bryostatin Scientific and Medical Reports References Chapter 13 DNA-Encoded Peptide Libraries and Drug Discovery Summary 1. Introduction 2. Methods for DNA-Encoded Peptide Display 3. Applications for DNA-Encoded Peptide Libraries 4. Conclusions References Chapter Mechanism-Based Highthroughput Screening for Novel Anticancer Drug Discovery Summary 1. Importance of Mechanism-Based Targets in Postgenomic Drug Discovery 2. High-Throughput Screening 3. Assay Technologies 4. Assay Performance and Downstream Evaluation of Bits 5. Compounds for HTS 6. Examples of Compounds Identified Through Screening Approaches 7. Future HTS Developments 8. Concluding Remarks References Chapter 15 Tumor Cell Cultures in Drug Development Summary 1. Introduction 2. Growth Inhibition Assays 3. Clonogenic Assays 4. Three-Dimensional Cell Cultures: Modeling Extravascular Drug Transport 5. Modeling of in Vivo Activity by in Vitro Assays 6. Perspective References Chapter 16 Screening Using Animal Systems Summary 1. Introduction 2. Choice of in Vivo Systems for Large-Scale Drug Development 3. Combined in Vitro/in Vivo Testing Procedure Using Human Tumor Xenografts-The Freiburg Experience 4. Use of Transgenic Animals in the Search for New Drugs 5. Screening for Angiogenesis Inhibitors References Chapter 17 Relevance of Preclinical Pharmacology and Toxicology to Phase I Trial Extrapolation Techniques: Elevance of Animal Toxicology Summary 1. Introduction 2. Historical Perspective 3. Special Toxicity Evaluations 4. Recent Examples of Drug Development at NCI 5. Predictability of Nonclinical Animal Data 6. Conclusions References Chapter 18 Clinical Trial Design: Incorporation of Pharmacokinetic, Pharmacodynamic, and Pharmacogenetic Principles Summary 1. Introduction 2. Rationale for Chemotherapy Optimization 3. Pharmacokinetic-Pharmacodynamic Relationships 4. Pharmacogenetics 5. Strategies to Improve Therapeutic Index 6. Conclusion and Perspectives References Chapter 19 Tumor Imaging Applications in the Testing of New Drugs Summary 1. Introduction 2. Positron Emission Tomography 3. PET in New Drug Evaluation 4. Conclusions References Chapter 20 Mechanistic Approaches to Phase I Clinical Trials Summary 1. Introduction 2. Mechanism-Based Studies of Established Anticancer Agents to Assess Target Inhibition 3. Mechanistic Trial Perspectives on Anticancer Agents with Novel Mechanisms 4. Potential of PET Scanning in the Assessment of Pharmacodynamic End Points 5. Conclusion References Index" @default.
• W1567784973 created "2016-06-24" @default.
• W1567784973 creator A5038254746 @default.
• W1567784973 creator A5061684371 @default.
• W1567784973 date "2002-01-01" @default.
• W1567784973 modified "2023-09-26" @default.
• W1567784973 title "Anticancer Drug Development" @default.
• W1567784973 doi "https://doi.org/10.1016/b978-0-12-072651-6.x5000-1" @default.
• W1567784973 hasPublicationYear "2002" @default.
• W1567784973 type Work @default.
• W1567784973 sameAs 1567784973 @default.
• W1567784973 citedByCount "9" @default.
• W1567784973 countsByYear W15677849732012 @default.
• W1567784973 countsByYear W15677849732013 @default.
• W1567784973 countsByYear W15677849732014 @default.
• W1567784973 crossrefType "book" @default.
• W1567784973 hasAuthorship W1567784973A5038254746 @default.
• W1567784973 hasAuthorship W1567784973A5061684371 @default.
• W1567784973 hasConcept C101544691 @default.
• W1567784973 hasConcept C105696609 @default.
• W1567784973 hasConcept C121608353 @default.
• W1567784973 hasConcept C184235292 @default.
• W1567784973 hasConcept C190283241 @default.
• W1567784973 hasConcept C2779013556 @default.
• W1567784973 hasConcept C29537977 @default.
• W1567784973 hasConcept C31573885 @default.
• W1567784973 hasConcept C42362537 @default.
• W1567784973 hasConcept C502942594 @default.
• W1567784973 hasConcept C54355233 @default.
• W1567784973 hasConcept C55493867 @default.
• W1567784973 hasConcept C57074206 @default.
• W1567784973 hasConcept C62478195 @default.
• W1567784973 hasConcept C86803240 @default.
• W1567784973 hasConcept C95444343 @default.
• W1567784973 hasConcept C96232424 @default.
• W1567784973 hasConceptScore W1567784973C101544691 @default.
• W1567784973 hasConceptScore W1567784973C105696609 @default.
• W1567784973 hasConceptScore W1567784973C121608353 @default.
• W1567784973 hasConceptScore W1567784973C184235292 @default.
• W1567784973 hasConceptScore W1567784973C190283241 @default.
• W1567784973 hasConceptScore W1567784973C2779013556 @default.
• W1567784973 hasConceptScore W1567784973C29537977 @default.
• W1567784973 hasConceptScore W1567784973C31573885 @default.
• W1567784973 hasConceptScore W1567784973C42362537 @default.
• W1567784973 hasConceptScore W1567784973C502942594 @default.
• W1567784973 hasConceptScore W1567784973C54355233 @default.
• W1567784973 hasConceptScore W1567784973C55493867 @default.
• W1567784973 hasConceptScore W1567784973C57074206 @default.
• W1567784973 hasConceptScore W1567784973C62478195 @default.
• W1567784973 hasConceptScore W1567784973C86803240 @default.
• W1567784973 hasConceptScore W1567784973C95444343 @default.
• W1567784973 hasConceptScore W1567784973C96232424 @default.
• W1567784973 hasLocation W15677849731 @default.
• W1567784973 hasOpenAccess W1567784973 @default.
• W1567784973 hasPrimaryLocation W15677849731 @default.
• W1567784973 hasRelatedWork W1448090449 @default.
• W1567784973 hasRelatedWork W1969855931 @default.
• W1567784973 hasRelatedWork W1986714349 @default.
• W1567784973 hasRelatedWork W2001703565 @default.
• W1567784973 hasRelatedWork W2031828269 @default.
• W1567784973 hasRelatedWork W2084390278 @default.
• W1567784973 hasRelatedWork W2084675748 @default.
• W1567784973 hasRelatedWork W2093326535 @default.
• W1567784973 hasRelatedWork W2112773270 @default.
• W1567784973 hasRelatedWork W2156521880 @default.
• W1567784973 hasRelatedWork W2168508278 @default.
• W1567784973 hasRelatedWork W2169212902 @default.
• W1567784973 hasRelatedWork W2357610971 @default.
• W1567784973 hasRelatedWork W2411346470 @default.
• W1567784973 hasRelatedWork W2415471698 @default.
• W1567784973 hasRelatedWork W2794930605 @default.
• W1567784973 hasRelatedWork W2952326265 @default.
• W1567784973 hasRelatedWork W3213557594 @default.
• W1567784973 hasRelatedWork W2116939855 @default.
• W1567784973 hasRelatedWork W2280484895 @default.
• W1567784973 isParatext "false" @default.
• W1567784973 isRetracted "false" @default.
• W1567784973 magId "1567784973" @default.
• W1567784973 workType "book" @default.